glp-1 drugs semaglutide GLP-1s GLP-1 Agonists - What is

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

After a median follow-up of 2.5 years, GLP-1 RAs users had lower risks of mortality (adjusted hazard ratio (aHR), 0.39

Mechanisms underlying long-term sustained weight loss and glycemic normalization after obesity surgery include changes in gut hormone levels, including glucagon-like peptide 1 (GLP-1) and peptide YY (PYY)

Framed as three eras (2025-2026

Expert perspectives Reacting to the readout, endocrinologist Daniel J

Discover if Zepbound is the right treatment for you.